A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study

Madeline Bauer, Gregory H. Reaman, Jacquelyn A. Hank, Mitchell S. Cairo, Peter Anderson, Bruce R. Blazar, Sharon Frierdich, Paul M. Sondel

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study'. Together they form a unique fingerprint.

Medicine & Life Sciences